Mohamed A. Yassin

Doha, DA, Qatar

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 402 publications

Precision Medicine in Transfusion-Dependent and Non-Transfusion-Dependent β-Thalassemia: Toward Personalized Diagnosis and Therapy.

Precision Medicine in Transfusion-Dependent and Non-Transfusion-Dependent β-Thalassemia: Toward Personalized Diagnosis and Therapy.

Journal: Hemoglobin

Published: August 10, 2026

Caplacizumab-Enabled Treatment of Immune-Mediated Thrombotic Thrombocytopenic Purpura Without Plasma Exchange: Evidence, Patient Selection, and Practical Considerations.

Caplacizumab-Enabled Treatment of Immune-Mediated Thrombotic Thrombocytopenic Purpura Without Plasma Exchange: Evidence, Patient Selection, and Practical Considerations.

Journal: Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis

Published: August 03, 2026

Dose Optimization of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis of 50 mg Versus 100 mg Once Daily.

Dose Optimization of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis of 50 mg Versus 100 mg Once Daily.

Journal: Clinical lymphoma, myeloma & leukemia

Published: June 12, 2026

Beyond Chemoimmunotherapy: Emerging Cellular and Targeted Therapies in Transformed Follicular Lymphoma: A Scoping Review.

Beyond Chemoimmunotherapy: Emerging Cellular and Targeted Therapies in Transformed Follicular Lymphoma: A Scoping Review.

Journal: Cancer control : journal of the Moffitt Cancer Center

Published: June 10, 2026

Practical Guide for Managing Philadelphia-Negative Myeloproliferative Neoplasms in Patients with Organ Dysfunction.

Practical Guide for Managing Philadelphia-Negative Myeloproliferative Neoplasms in Patients with Organ Dysfunction.

Journal: Oncology

Published: May 16, 2026

Precision medicine in myelofibrosis: from molecular profiling to personalized therapy.

Precision medicine in myelofibrosis: from molecular profiling to personalized therapy.

Journal: Frontiers in oncology

Published: May 10, 2026

Review of Bleeding as Initial Presentation in Patients with Chronic Myeloid Leukemia.

Review of Bleeding as Initial Presentation in Patients with Chronic Myeloid Leukemia.

Journal: Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis

Published: April 27, 2026

Hyperbaric Oxygen Therapy in Sickle Cell Disease: A Narrative Review of Mechanisms, Clinical Applications, and Future Directions.

Hyperbaric Oxygen Therapy in Sickle Cell Disease: A Narrative Review of Mechanisms, Clinical Applications, and Future Directions.

Journal: Hemoglobin

Published: April 24, 2026

Redefining Fitness in Chronic Lymphocytic Leukemia: A Treatment-Specific Framework forthe Targeted Therapy Era.

Redefining Fitness in Chronic Lymphocytic Leukemia: A Treatment-Specific Framework forthe Targeted Therapy Era.

Journal: Oncology

Published: April 22, 2026

Beyond Bleeding: Underrecognized Thrombotic Complications in Acute Promyelocytic Leukemia - A Single-Center Experience from the GCC Region.

Beyond Bleeding: Underrecognized Thrombotic Complications in Acute Promyelocytic Leukemia - A Single-Center Experience from the GCC Region.

Journal: Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis

Published: April 20, 2026

BIO26-034: Electronic PowerPlan Transforming Blinatumomab Treatment Into a Safe, and Efficient Workflow.

BIO26-034: Electronic PowerPlan Transforming Blinatumomab Treatment Into a Safe, and Efficient Workflow.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 16, 2026

QIM26-286: Ambulatory Blinatumomab via Infusion Pump: A FMEA-Driven Quality Improvement to Reduce Bed Utilization and Elevate Patient/Staff Experience and Decrease Cost.

QIM26-286: Ambulatory Blinatumomab via Infusion Pump: A FMEA-Driven Quality Improvement to Reduce Bed Utilization and Elevate Patient/Staff Experience and Decrease Cost.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 16, 2026

Showing 1-12 of 402

Last Updated: 09/26/2026